129 related articles for article (PubMed ID: 29499398)
21. Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients.
Kato A; Sato N; Sugawara T; Takahashi K; Kito M; Makino K; Sato T; Shimizu D; Shirasawa H; Miura H; Sato W; Kumazawa Y; Sato A; Kumagai J; Terada Y
Am J Surg Pathol; 2016 Jun; 40(6):770-6. PubMed ID: 26848797
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic mechanisms in the pathogenesis of Lynch syndrome.
Peltomäki P
Clin Genet; 2014 May; 85(5):403-12. PubMed ID: 24443998
[TBL] [Abstract][Full Text] [Related]
23. Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma.
Stark AM; Doukas A; Hugo HH; Hedderich J; Hattermann K; Maximilian Mehdorn H; Held-Feindt J
Neurol Res; 2015 Feb; 37(2):95-105. PubMed ID: 24995467
[TBL] [Abstract][Full Text] [Related]
24. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.
Jessup CJ; Redston M; Tilton E; Reimann JD
Hum Pathol; 2016 Mar; 49():1-9. PubMed ID: 26826402
[TBL] [Abstract][Full Text] [Related]
25. Methylation and expression analysis of mismatch repair genes in extramammary Paget's disease.
Kang Z; Zhu Y; Zhang QA; Dong L; Xu F; Zhang X; Guan M
J Eur Acad Dermatol Venereol; 2019 May; 33(5):874-879. PubMed ID: 30784122
[TBL] [Abstract][Full Text] [Related]
26. Epigenetic modifications of DAPK and p16 genes contribute to arsenic-induced skin lesions and nondermatological health effects.
Banerjee N; Paul S; Sau TJ; Das JK; Bandyopadhyay A; Banerjee S; Giri AK
Toxicol Sci; 2013 Oct; 135(2):300-8. PubMed ID: 23872714
[TBL] [Abstract][Full Text] [Related]
27. Microsatellite instability, promoter methylation and protein expression of the DNA mismatch repair genes in epithelial ovarian cancer.
V S; Bhagat R; C S P; V R P; Krishnamoorthy L
Genomics; 2014 Oct; 104(4):257-63. PubMed ID: 25192888
[TBL] [Abstract][Full Text] [Related]
28. Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population.
Lagerstedt-Robinson K; Rohlin A; Aravidis C; Melin B; Nordling M; Stenmark-Askmalm M; Lindblom A; Nilbert M
Oncol Rep; 2016 Nov; 36(5):2823-2835. PubMed ID: 27601186
[TBL] [Abstract][Full Text] [Related]
29. Mismatch repair deficiency screening in colorectal carcinoma by a four-antibody immunohistochemical panel in Pakistani population and its correlation with histopathological parameters.
Hashmi AA; Ali R; Hussain ZF; Faridi N; Khan EY; Bakar SMA; Edhi MM; Khan M
World J Surg Oncol; 2017 Jun; 15(1):116. PubMed ID: 28651545
[TBL] [Abstract][Full Text] [Related]
30. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
31. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
[TBL] [Abstract][Full Text] [Related]
32. Contributions by MutL homologues Mlh3 and Pms2 to DNA mismatch repair and tumor suppression in the mouse.
Chen PC; Dudley S; Hagen W; Dizon D; Paxton L; Reichow D; Yoon SR; Yang K; Arnheim N; Liskay RM; Lipkin SM
Cancer Res; 2005 Oct; 65(19):8662-70. PubMed ID: 16204034
[TBL] [Abstract][Full Text] [Related]
33. Microsatellite instability: an update.
Yamamoto H; Imai K
Arch Toxicol; 2015 Jun; 89(6):899-921. PubMed ID: 25701956
[TBL] [Abstract][Full Text] [Related]
34. Interdependence of DNA mismatch repair proteins MLH1 and MSH2 in apoptosis in human colorectal carcinoma cell lines.
Hassen S; Ali AA; Kilaparty SP; Al-Anbaky QA; Majeed W; Boman BM; Fields JZ; Ali N
Mol Cell Biochem; 2016 Jan; 412(1-2):297-305. PubMed ID: 26728996
[TBL] [Abstract][Full Text] [Related]
35. The added value of PMS2 immunostaining in the diagnosis of hereditary nonpolyposis colorectal cancer.
Halvarsson B; Lindblom A; Rambech E; Lagerstedt K; Nilbert M
Fam Cancer; 2006; 5(4):353-8. PubMed ID: 16817031
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer.
Truninger K; Menigatti M; Luz J; Russell A; Haider R; Gebbers JO; Bannwart F; Yurtsever H; Neuweiler J; Riehle HM; Cattaruzza MS; Heinimann K; Schär P; Jiricny J; Marra G
Gastroenterology; 2005 May; 128(5):1160-71. PubMed ID: 15887099
[TBL] [Abstract][Full Text] [Related]
37. Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer.
Chen Y; Wang J; Fraig MM; Henderson K; Bissada NK; Watson DK; Schweinfest CW
Int J Oncol; 2003 May; 22(5):1033-43. PubMed ID: 12684669
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma.
Hall G; Clarkson A; Shi A; Langford E; Leung H; Eckstein RP; Gill AJ
Pathology; 2010; 42(5):409-13. PubMed ID: 20632815
[TBL] [Abstract][Full Text] [Related]
39. Assessing how reduced expression levels of the mismatch repair genes MLH1, MSH2, and MSH6 affect repair efficiency.
Kansikas M; Kasela M; Kantelinen J; Nyström M
Hum Mutat; 2014 Sep; 35(9):1123-7. PubMed ID: 24924810
[TBL] [Abstract][Full Text] [Related]
40. Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.
Skeldon SC; Semotiuk K; Aronson M; Holter S; Gallinger S; Pollett A; Kuk C; van Rhijn B; Bostrom P; Cohen Z; Fleshner NE; Jewett MA; Hanna S; Shariat SF; Van Der Kwast TH; Evans A; Catto J; Bapat B; Zlotta AR
Eur Urol; 2013 Feb; 63(2):379-85. PubMed ID: 22883484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
